<DOC>
	<DOCNO>NCT02067182</DOCNO>
	<brief_summary>Oral anticoagulation treatment ( OAC ) follow clinically successful catheter abla-tion atrial fibrillation ( AF ) controversial . Recent guideline recommend con-tinuation OAC patient CHA2DS2VASc score ≥2 even evidence recurrent AF ( Camm JA et al. , Eur Heart J 2012 ) . The net clinical ben-efit OAC successful ablation patient remain extent un-clear . As OAC bear risk bleed event , ODIn-AF study aim evalu-ate positive effect OAC incidence silent cerebral embolic event patient high risk embolic event , free AF successful pulmo-nary vein ablation . ODIn-AF aim determine continue administration dabigatran superior preven-tion silent cerebral embolism discontinuation OAC 3 month pa-tients free symptomatic AF-episodes CHA2DS2VASc score ≥2 first pulmonary vein ablation paroxysmal AF .</brief_summary>
	<brief_title>Prevention Silent Cerebral Thromboembolism Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Written inform consent Patients schedule circumferential antral PV ablation nonvalvular ( mitral regurgitation less moderate severe ; relevant mitral stenosis mean pressure gradient &gt; 5mmHg ) symptomatic , paroxysmal AF persistent AF ( duration &lt; 12 month ) use cool tip RF cryoballooncatheter CHA2DS2VASc score ≥ 2 Randomization criterion : Sinus rhythm AF ablation ( assessed 72h Holter ECG ) follow 3 month blank period No clinical evidence recurrent AF complete 3 month blank period assess symptom Lack write informed consent Severe mental disorder , drug alcohol addiction ( &gt; 8 drinks/week ) Pregnancy/breast feed Severely impaired renal function , GFR &lt; 30 ml/min Impaired liver function ( ALT/AST transaminase count 3fold high normal value ) Age &gt; 80 year Valvular ( less moderate severe ; relevant mitral stenosis mean pressure gradient &gt; 5mmHg ) AF Long stand persistent ( &gt; 12 month ) permanent AF NSTEMI/STEMI/implantated drug elute stent indication dual antiplatelet therapy within 12 month enrolment History leave atrial ablation procedure Clinical indication extend left atrial ablation procedure ( line , CFAE , rotorablation ) History presence leave atrial ventricular thrombus History cardioembolic stroke / TIA History major bleed predisposition bleed incidence Cerebral lesion clinical situation organ system high risk severe bleed History previous surgery contraindication OAC History malignoma contraindication OAC Significant carotid stenosis Mechanical prosthetic heart valve indication permanent OAC Contraindication MRI Hypersensitivity dabigatran ingredient medicinal product Concomitant use another OAC heparines Concomitant medication dronedarone , ketoconazole , itraconazole , cyclosporine , tacrolimus interact drug specify drug information Simultaneous participation clinical trial involve administration investigational medicinal product within 30 day prior clinical trial begin Females childbearing potential , use willing use medically reliable method contraception entire study duration ( oral , injectable , implantable contraceptive , intrauterine contraceptive device ) unless surgically sterilize / hysterectomized criterion consider sufficiently reliable investigator individual case Conditions interfere study treatment discretion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>